05/26/2021
Cleveland Clinic names new head of innovation arm: 5 things to know
D. Geoffrey Vince, Ph.D., was tapped to lead Cleveland Clinic Innovations as executive director, a newly created role, the health system said May 26.
05/18/2021
Cleveland Clinic, Amwell joint venture expands virtual second opinions services: 4 details
The Clinic, a joint digital health venture between the Cleveland Clinic and Amwell, is launching new health offerings as part of its virtual second opinion service, the organizations said May 18.
05/05/2021
Cleveland Diagnostics Receives College of American Pathologists (CAP) Accreditation for Its Clinical Laboratory
Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received Laboratory Accreditation from the College of American Pathologists (CAP) for its CLIA certified reference lab. The CAP Accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards of laboratory quality, accuracy, and consistency.
04/28/2021
New Amwell telehealth platform offers connections to Cleveland Clinic, Google Cloud services
Amwell on April 28 unveiled its new Converge telehealth platform, which can host and operate digital offerings from Cleveland Clinic, Google Cloud and others.
04/28/2021
Tech Amwell rolls out new telehealth platform that integrates with digital health tools
Building on the massive shift to virtual care in the past year, telehealth giant Amwell launched a new telehealth platform with an open architecture to support other digital health applications like remote monitoring.
04/15/2021
Cardionomic Announces First Patients Enrolled in CPNS Pilot Study
Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their Cardionomic Pulmonary Neuromodulation System (CPNS) Pilot Study. The study will evaluate the safety and performance of the CPNS in patients suffering from Acute Decompensated Heart Failure, defined as new or worsening symptoms of heart failure. The first patients were enrolled by Temistocles Díaz, M.D., Principal Investigator at Pacifica Salud Hospital Punta Pacifica in Panama City, Panama. He was joined by Co-Investigators Thais Coronado, M.D. and Jose Pinto, M.D. Up to fifty patients are expected to be enrolled worldwide.
03/30/2021
Cleveland Clinic and IBM Unveil Landmark 10-Year Partnership to Accelerate Discovery in Healthcare and Life Sciences
Cleveland Clinic and IBM have announced a planned 10-year partnership to establish the Discovery Accelerator, a joint Cleveland Clinic – IBM center with the mission of fundamentally advancing the pace of discovery in healthcare and life sciences through the use of high performance computing on the hybrid cloud, artificial intelligence (AI) and quantum computing technologies.
03/12/2021
Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the European Patent Office has issued and published the first European patent for its novel ovarian cancer vaccine technology. This technology was invented and developed at Cleveland Clinic and Anixa is the worldwide licensee.
03/10/2021
Northeast Ohio gets a hefty share of Ohio Third Frontier commission awards
Case Western Reserve University, Cleveland Clinic, JumpStart Inc. and several other organizations and small companies in Northeast Ohio are among the recipients of a total of nearly $73 million from the Ohio Third Frontier Commission.
03/09/2021
OncoSynergy Announces First Patient Treated in First-in-Human Clinical Trial of OS2966 in Recurrent Glioblastoma
OncoSynergy, Inc., a physician-founded oncology company committed to advancing therapeutics to address dire unmet medical needs, announced today that the first patient was treated in the Company's First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida. OS2966 is a first-in-class immunotherapy, and the first ever anti-CD29 (beta 1 integrin) therapeutic to reach human trials.